Tigermed advances share buyback program, nearing 1% completion

** Hangzhou Tigermed Consulting (SZSE:300347) announced progress in its share repurchase program, initiated following shareholder approvals in February, April of 2024. The company has repurchased 9,806,300 A-shares, representing 1.1337% of the company's total share capital and 1.3219% of its A-share capital. The repurchases, conducted via centralized bidding, occurred at prices between RMB 48.17 and RMB 62.00 per share, totaling RMB 500,116,439.14 (excluding transaction costs). These shares will be used for equity incentives, employee stock ownership plans, or to reduce registered capital through cancellation. The buyback remains active with a total allocated budget between RMB 500 million and RMB 1 billion and a maximum purchase price of RMB 72 per share.